全文获取类型
收费全文 | 66291篇 |
免费 | 4663篇 |
国内免费 | 2306篇 |
专业分类
耳鼻咽喉 | 300篇 |
儿科学 | 915篇 |
妇产科学 | 998篇 |
基础医学 | 11310篇 |
口腔科学 | 923篇 |
临床医学 | 3581篇 |
内科学 | 10332篇 |
皮肤病学 | 1020篇 |
神经病学 | 9907篇 |
特种医学 | 803篇 |
外国民族医学 | 19篇 |
外科学 | 3987篇 |
综合类 | 7235篇 |
预防医学 | 1526篇 |
眼科学 | 584篇 |
药学 | 12659篇 |
5篇 | |
中国医学 | 1399篇 |
肿瘤学 | 5757篇 |
出版年
2024年 | 40篇 |
2023年 | 750篇 |
2022年 | 1018篇 |
2021年 | 1803篇 |
2020年 | 1730篇 |
2019年 | 1700篇 |
2018年 | 1743篇 |
2017年 | 1833篇 |
2016年 | 1830篇 |
2015年 | 2153篇 |
2014年 | 3663篇 |
2013年 | 4905篇 |
2012年 | 3674篇 |
2011年 | 4295篇 |
2010年 | 3551篇 |
2009年 | 3647篇 |
2008年 | 3952篇 |
2007年 | 3585篇 |
2006年 | 3108篇 |
2005年 | 2671篇 |
2004年 | 2522篇 |
2003年 | 2324篇 |
2002年 | 1861篇 |
2001年 | 1609篇 |
2000年 | 1448篇 |
1999年 | 1238篇 |
1998年 | 1285篇 |
1997年 | 1227篇 |
1996年 | 1048篇 |
1995年 | 975篇 |
1994年 | 899篇 |
1993年 | 804篇 |
1992年 | 600篇 |
1991年 | 555篇 |
1990年 | 412篇 |
1989年 | 352篇 |
1988年 | 297篇 |
1987年 | 271篇 |
1986年 | 288篇 |
1985年 | 338篇 |
1984年 | 276篇 |
1983年 | 169篇 |
1982年 | 232篇 |
1981年 | 184篇 |
1980年 | 129篇 |
1979年 | 78篇 |
1978年 | 54篇 |
1977年 | 41篇 |
1976年 | 32篇 |
1975年 | 30篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Journal of microbiology, immunology, and infection》2022,55(2):273-281
BackgroundStenotrophomonas maltophilia, a species of highly genetic diversity, has emerged as an important nosocomial pathogen. S. maltophilia and Pseudomonas aeruginosa are often co-isolated from pneumonia patients. In our previous study, we have demonstrated that the pacIRA cluster present in some but not all clinical S. maltophilia isolates. Proteins encoded by pacIRA operon are an extracytoplasmic function (ECF) sigma factor, a transmembrane anti-sigma regulator, and a TonB-dependent receptor. This study aimed to elucidate PacIRA system function and its significance to S. maltophilia.MethodsThe pacI, pacR, and pacA genes were individually or totally deleted from the chromosome of KJΔEnt, a pacIRA-positive and siderophore-null strain. Growth promotion assay was performed to examine the implication of pacIRA system in iron utilization. Gene expression was quantified by quantitative real time PCR (qRT-PCR). Growth competition assay was executed to investigate the significance of pacIRA operon to S. maltophilia.ResultsPacIRA system contributed to utilize ferri-pyochelin of P. aeruginosa as iron sources for growth in an iron-depleted condition, but hardly utilized ferric citrate, hemin, ferri-stenobactin, and ferri-pyoverdine. PacIRA was founded to belong to Fur regulon and upregulated in response to iron-depleted stress. Growth competition assay demonstrated that pacIRA-positive S. maltophilia had a superiority over pacIRA-negative S. maltophilia in iron acquisition when they were co-cultured in P. aeruginosa ferri-pyochelin-supplemented medium.ConclusionsPacIRA system of S. maltophilia is a xenosiderophore uptake implement, involving in the acquisition of pyochelin of P. aeruginosa. 相似文献
3.
4.
5.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
6.
《Saudi Pharmaceutical Journal》2022,30(5):595-604
Anthrax is a zoonotic infection caused by the gram-positive, aerobic, spore-forming bacterium Bacillus anthracis. Depending on the origin of the infection, serious health problems or mortality is possible. The virulence of B. anthracis is reliant on three pathogenic factors, which are secreted upon infection: protective antigen (PA), lethal factor (LF), and edema factor (EF). Systemic illness results from LF and EF entering cells through the formation of a complex with the heptameric form of PA, bound to the membrane of infected cells through its receptor. The currently available anthrax vaccines have multiple drawbacks, and recombinant PA is considered a promising second-generation vaccine candidate. However, the inherent chemical instability of PA through Asn deamidation at multiple sites prevents its use after long-term storage owing to loss of potency. Moreover, there is a distinct possibility of B. anthracis being used as a bioweapon; thus, the developed vaccine should remain efficacious and stable over the long-term. Second-generation anthrax vaccines with appropriate adjuvant formulations for enhanced immunogenicity and safety are desired. In this article, using protein engineering approaches, we have reviewed the stabilization of anthrax vaccine candidates that are currently licensed or under preclinical and clinical trials. We have also proposed a formulation to enhance recombinant PA vaccine potency via adjuvant formulation. 相似文献
7.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
8.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
9.
10.
目的 慢性牙周炎表现的病理性骨吸收非常常见,牙周膜干细胞(PDLSCs)的外泌体(Exo)对骨吸收的作用和影响尚不明确,本研究分析了该Exo蛋白组分对破骨细胞分化的影响。方法 分别从正畸前拔牙患者和慢性牙周炎患者的牙周膜组织中提取PDLSCs,通过流式细胞术检测表面标记物;通过差速离心分别提取2种细胞的Exo,即Exo-WT和Exo-CP,并通过Western blot、透射电子显微镜(TEM)、蛋白浓度检测、纳米粒径追踪检测Exo特征;通过蛋白质谱检测2种Exo的蛋白组分;通过酶联免疫吸附(ELISA)验证了差异表达蛋白肿瘤坏死因子α(TNF-α)、核因子κB受体活化因子配体(RANKL)、白细胞介素(IL)-1α、转化生长因子β(TGF-β)、骨形态发生蛋白2(BMP-2)表达水平;将10、100、1 000 μg·mL-1的Exo-CP或Exo-WT加入RAW264.7培养基中并于5 d时通过实时荧光定量聚合酶链反应(RT-qPCR)、Western blot、抗酒石酸酸性磷酸酶(TRAP)染色检测破骨分化相关指标表达情况;采用SPSS 24.0软件对实验数据进行统计学分析。结果 Exo-CP富集的差异表达蛋白主要与破骨细胞分化的TNF信号通路、核转录因子κB(NF-κB)信号通路相关;ELISA实验证实了Exo-CP中高表达TNF-α、RANKL、IL-1α,低表达TGF-β1、BMP-2(P<0.05);Exo-CP作用于RAW264.7,显著提高了细胞的破骨分化相关基因及蛋白的表达水平,TRAP染色可见分化的破骨细胞,且呈现浓度依赖性,100、1 000 μg·mL-1浓度Exo-CP对破骨细胞分化的促进作用显著高于10 μg·mL-1浓度组(P<0.05)。结论 慢性牙周炎的病理性骨吸收可能由炎性PDLSCs所分泌的Exo通过促进破骨细胞分化引起,Exo中主要的作用蛋白可能为RANKL和TNF-α,本研究为慢性牙周炎骨吸收的发病机制提供了新视角。 相似文献